Naveed Sattar summarizes the findings of the EMPA-REG Outcome trial, and what this tells us about potential mechanisms that led to the observed CV benefit with the SGTL2 inhibitor empagliflozin.
This lecture by prof Naveed Sattar was part of a CME accredited symposium: Contemporary management of a patient with Heart Failure and diabetes: Implications from recent trials?' held at ESC Heart Failure 2018 in Vienna, Austria.
Naveed Sattar , MD is Professor of Metabolic Medicine, University of Glasgow. He is an academic (active clinically) experienced in biomarker studies/trials investigating the causes, prevention and management of diabetes, obesity and heart disease.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- Contemporary management of a patient with heart failure and diabetes: Implications from recent trialsGuidance from outcome trials: What are the clinical implications?
Prof. Faiez Zannad, MD
- Contemporary management of a patient with heart failure and diabetes: Implications from recent trialsCurrent management of heart failure and T2DM
Prof. Martin Cowie